M&L Healthcare
Investor profile | Builders Republic
About
M&L Healthcare is the healthcare family office of the Kum family, based in Singapore and established in 2019 under the name M&L Healthcare Investments Pte. Ltd. The structure is owned by Grandline International and invests long-term in medtechs, life sciences, and therapies addressing unmet medical needs. Its official portfolio includes 20 companies, including LimFlow, acquired by Inari Medical in November 2023, leaving 19 current holdings. M&L Healthcare invests from seed to growth stage, with no public check size disclosed. Among its holdings are CorWave, Tissium, FineHeart, Iktos, Hepta Medical, SafeHeal, Endovascular Engineering, and Xeltis. In France, the family office participated in CorWave's Series C in 2021, Hepta Medical's Series A in 2024, and SafeHeal's Series C in 2025; it also participated in Hepta's extension in 2026. For a medtech looking to combine patient funding with international family shareholding, M&L Healthcare is a specialized partner to consider alongside a lead investor.
Key facts
- Type
- Family Office
- Stages
- Seed, Series A, Series B, Growth
- Headquarters
- Singapore
- Offices
- Singapore
- Geographic focus
- Global
- Founded
- 2019
Track record
- Portfolio companies: 19
- Total investments: 20
- Exits: 1
Notable investments
CorWave (FR), Tissium (FR), FineHeart (FR), Iktos (FR), Hepta Medical (FR), SafeHeal (FR), Endovascular Engineering (US), Xeltis (NL)